Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery
Surgery may leads to higher serious adverse events (number of events) compared with radiofrequency ablation (low certainty).
1 finding from 1 review
Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes serious adverse events (number of events) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Serious adverse events · adults and children with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults and children with enteric fever
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with active UC
It is very uncertain whether probiotics changes serious adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with 5‐aminosalicylic acid (very low certainty).
1 finding from 1 review
Serious adverse events · adults with bronchiectasis
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 40 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (moderate certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 120 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether laser ablation changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether transarterial embolisation plus radiofrequency ablation changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether transarterial embolisation plus percutaneous alcohol injection changes serious adverse events (number of participants) compared with percutaneous alcohol injection (very low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma eligible for surgery
Surgery may leads to higher serious adverse events (number of participants) compared with radiofrequency ablation (low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether percutaneous alcohol injection changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events (hand‐foot skin reaction) · people with hepatocellular carcinoma
Radioembolisation may leads to lower non‐serious adverse events (hand‐foot skin reaction) compared with sorafenib (low certainty).
1 finding from 1 review
Non‐serious adverse events: total bilirubin elevation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: total bilirubin elevation compared with TACE (very low certainty).
1 finding from 1 review